

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM369845

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	MERGER		
<b>EFFECTIVE DATE:</b>	11/14/2007		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Halozyme Therapeutics, Inc.		11/14/2007	CORPORATION: NEVADA
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Halozyme Therapeutics, Inc.		
<b>Street Address:</b>	11588 Sorrento Valley Road, Suite 17		
<b>City:</b>	San Diego		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	92121		
<b>Entity Type:</b>	CORPORATION: DELAWARE		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	3061136	CUMULASE	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	4152687522		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	415-268-7000		
<b>Email:</b>	ksamia@mofo.com		
<b>Correspondent Name:</b>	Jennifer Lee Taylor		
<b>Address Line 1:</b>	425 Market Street		
<b>Address Line 2:</b>	c/o Morrison & Foerster LLP		
<b>Address Line 4:</b>	San Francisco, CALIFORNIA 94105		
<b>ATTORNEY DOCKET NUMBER:</b>	57617-6002000		
<b>NAME OF SUBMITTER:</b>	Jennifer Lee Taylor		
<b>SIGNATURE:</b>	/JLT2/		
<b>DATE SIGNED:</b>	01/20/2016		
<b>Total Attachments: 3</b>			
source=MERGER#page1.tif			
source=MERGER#page2.tif			
source=MERGER#page3.tif			

CH \$40.00 3061136

**CERTIFICATE OF MERGER**

of

**Halozyme Therapeutics, Inc.**  
(a Nevada corporation)

with and into

**Halozyme Therapeutics, Inc.**  
(a Delaware corporation)

The undersigned corporation, Halozyme Therapeutics, Inc., a Delaware corporation, hereby certifies:

**FIRST:** That the name and state of incorporation of each of the constituent corporations of the merger is as follows:

<u>Name</u>	<u>State of Incorporation</u>
Halozyme Therapeutics, Inc.	Nevada
Halozyme Therapeutics, Inc.	Delaware

**SECOND:** That an Agreement and Plan of Merger dated as of November 14, 2007, by and between Halozyme Therapeutics, Inc., a Nevada corporation and Halozyme Therapeutics, Inc. a Delaware corporation (the "Merger Agreement") has been approved, adopted, certified, executed and acknowledged by each of the constituent corporations in accordance with the requirements of subsection (c) of Section 252 of the General Corporation Law of the State of Delaware.

**THIRD:** That the name of the corporation surviving the merger is Halozyme Therapeutics, Inc. (the "Surviving Corporation"). The Surviving Corporation is a corporation of the State of Delaware.

**FOURTH:** The Certificate of Incorporation of the Surviving Corporation shall continue to be the Certificate of Incorporation of Halozyme Therapeutics, Inc., a Delaware corporation, as currently in effect.

**FIFTH:** That the executed Agreement and Plan of Merger is on file at the principal place of business of the Surviving Corporation. The address of said principal place of business is 11588 Sorrento Valley Road, Suite 17, San Diego, California 92121.

**SIXTH:** That a copy of the Agreement and Plan of Merger will be furnished by the Surviving Corporation upon request and without charge to any stockholder of any constituent corporation.


**SEVENTH:** The authorized capital stock of Halozyme Therapeutics, Inc., a Nevada corporation, as of the date of this Certificate of Merger is 150,000,000 shares of Common Stock, \$0.001 per share par value, and 20,000,000 shares of Preferred Stock, \$0.001 per share par value.

**EIGHTH:** This Certificate of Merger shall be effective immediately upon filing.

\* \* \* \* \*

IN WITNESS WHEREOF, the undersigned has caused this Certificate of Merger to be executed by its duly authorized officer this 14th day of November, 2007.

HALOZYME THERAPEUTICS, INC.  
a Delaware corporation

By:   
\_\_\_\_\_  
Jonathan E. Lim  
President and Chief Executive Officer